Special lssues
Table of Content

Cell Death in Health and Disease: Diversity, Complexity, and Dynamics

Submission Deadline: 30 September 2024 Submit to Special Issue

Guest Editors

Lingfeng Luo, Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, USA. lingfeng@stanford.edu
Wan-Xi Yang, The Sperm Laboratory, College of Life Sciences, Zhejiang University, China. wxyang@spermlab.org

Summary

This special issue is dedicated to the exploration of molecular mechanisms and signaling pathways governing cell death in both physiological and pathological contexts. Cell death is a fundamental process in embryonic development, tissue homeostasis, immune responses, and the progression of diseases in multicellular organisms. Since the 1960s, when the regulated/programmed nature of cell death was first discovered, our understanding has expanded significantly. Beyond the well-known programmed apoptotic cell death (apoptosis) and non-programmed cell death (necrosis), recent decades have seen the identification of various forms of programmed non-apoptotic cell death, including but not limited to autophagy, necroptosis, parthanatos, ferroptosis, pyroptosis, NETosis, entosis, methuosis, and paraptosis.

 

The diversity and complexity of cell death patterns continue to evolve, as exemplified by the recent recognition of PANoptosis, a novel proinflammatory cell death type sharing features with pyroptosis, apoptosis, and necroptosis. The discovery of new forms of cell death remains an ongoing process. Simultaneously, interventions in cell death pathways have played a substantial role in cancer therapies, traditionally focusing on apoptosis. Recent pre-clinical studies have expanded the potential applications of cell death-based therapies to autoimmune diseases, infectious diseases, atherosclerosis, ischemia/reperfusion injury, neurodegenerative disorders, and various other diseases or injuries.

 

Despite decades of intensive investigation into cell death, numerous puzzles remain unsolved. This special issue aims to curate original research and review articles that advance our comprehension of the molecular mechanisms and signaling networks associated with cell death across diverse pathophysiological scenarios. Furthermore, it endeavors to illuminate current or potential clinical and therapeutic implications of targeting cell death.

 

Potential topics include but are not limited to the following:

 

Novel biochemical and molecular mechanisms underlying cell death pathways.

Updates on the role of cell death in organism development and homeostasis.

Advances in both apoptotic and non-apoptotic cell death pathways.

Genetic control of cell death and the associated signaling networks.

Metabolic regulation of cell death and homeostasis.

The role of mitochondria in cell death.

Cell death's contribution to age-related diseases.

Translational implications and limitations of targeting cell death across different diseases.

Dissecting cell death in the multi-omics era.


Keywords

cell death, apoptosis, necrosis, autophagy, necroptosis, ferroptosis, pyroptosis, embryonic development, homeostasis, cancer therapy, autoimmune, infection, inflammation

Published Papers


  • Open Access

    REVIEW

    Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer

    LISHA MA, WANQI SHAO, WEILI ZHU
    BIOCELL, Vol.48, No.3, pp. 379-386, 2024, DOI:10.32604/biocell.2024.047812
    (This article belongs to the Special Issue: Cell Death in Health and Disease: Diversity, Complexity, and Dynamics)
    Abstract The morbidity rate of ovarian cancer, a malignant tumour in gynaecological tumours, is rising, and it is considered to be the most lethal cancer. The majority of patients are typically diagnosed during the advanced stages of the illness due to the elusive characteristics of ovarian cancer and an absence of highly sensitive and specific diagnostic indicators. Surgical excision of the lesions, along with chemotherapy, is the conventional treatment for ovarian cancer; however, resistance to platinum-based chemotherapeutic drugs and molecular targeted therapies frequently arises. Improving the survival rate and prognosis of patients with end-stage or recurring… More >

Share Link